{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T07:54:14Z","timestamp":1768290854717,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["1R41DA053081"],"award-info":[{"award-number":["1R41DA053081"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"NIAAA","doi-asserted-by":"crossref","award":["K01AA024796"],"award-info":[{"award-number":["K01AA024796"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIH\/NIAID","award":["P30AI027757"],"award-info":[{"award-number":["P30AI027757"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Federal and state regulations require frequent direct observation of methadone ingestion at an Opioid Treatment Program (OTP)\u2014a requirement that creates barriers to patient access. Video observed therapy (VOT) may help to address public health and safety concerns of providing take-home medications while simultaneously reducing barriers to treatment access and long-term retention. Evaluating user experiences with VOT is important for understanding the acceptability of this strategy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a qualitative evaluation of a clinical pilot program of VOT via smartphone that was rapidly implemented between April and August 2020 during the COVID-19 pandemic within three opioid treatment programs. In the program, selected patients submitted video recordings of themselves ingesting methadone take-home doses, which were asynchronously reviewed by their counselor. We recruited participating patients and counselors for semi-structured, individual interviews to explore their VOT experiences after program completion. Interviews were audio recorded and transcribed. Transcripts were analyzed using thematic analysis to identify key factors influencing acceptability and the effect of VOT on the treatment experience.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We interviewed 12 of the 60 patients who participated in the clinical pilot and 3 of the 5 counselors. Overall, patients were enthusiastic about VOT, noting multiple benefits over traditional treatment experiences, including avoiding frequent travel to the clinic. Some noted how this allowed them to better meet recovery goals by avoiding a potentially triggering environment. Most appreciated having increased time to devote to other life priorities, including maintaining consistent employment. Participants described how VOT increased their autonomy, allowed them to keep treatment private, and normalized treatment to align with other medications that do not require in-person dosing. Participants did not describe major usability issues or privacy concerns with submitting videos. Some participants reported feeling disconnected from counselors while others felt more connected. Counselors felt some discomfort in their new role confirming medication ingestion but saw VOT as a useful tool for select patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>VOT may be an acceptable tool to achieve equipoise between lowering barriers to treatment with methadone and protecting the health and safety of patients and their communities.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13722-023-00372-3","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T12:03:42Z","timestamp":1680091422000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["\u201cSign Me Up\u201d: a qualitative study of video observed therapy (VOT) for patients receiving expedited methadone take-homes during the COVID-19 pandemic"],"prefix":"10.1186","volume":"18","author":[{"given":"James B.","family":"Darnton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elenore P.","family":"Bhatraju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Beima-Sofie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyssa","family":"Michaels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin A.","family":"Hallgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Soth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Grekin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Woolworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0877-5399","authenticated-orcid":false,"given":"Judith I.","family":"Tsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,29]]},"reference":[{"key":"372_CR1","unstructured":"National Survey of Substance Abuse Treatment Services (N-SSATS): 2020, Data On Substance Abuse Treatment Facilities|CBHSQ Data. https:\/\/www.samhsa.gov\/data\/report\/national-survey-substance-abuse-treatment-services-n-ssats-2020-data-substance-abuse. Accessed 1 Sep 2022."},{"issue":"9","key":"372_CR2","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1007\/s10461-020-02887-1","volume":"24","author":"KM Peavy","year":"2020","unstructured":"Peavy KM, Darnton J, Grekin P, et al. Rapid implementation of service delivery changes to mitigate COVID-19 and maintain access to methadone among persons with and at high-risk for HIV in an opioid treatment program. AIDS Behav. 2020;24(9):2469\u201372. https:\/\/doi.org\/10.1007\/s10461-020-02887-1.","journal-title":"AIDS Behav"},{"key":"372_CR3","doi-asserted-by":"publisher","first-page":"108246","DOI":"10.1016\/j.jsat.2020.108246","volume":"123","author":"D Frank","year":"2021","unstructured":"Frank D. A chance to do it better: methadone maintenance treatment in the age of Covid-19. J Subst Abuse Treat. 2021;123:108246. https:\/\/doi.org\/10.1016\/j.jsat.2020.108246.","journal-title":"J Subst Abuse Treat"},{"key":"372_CR4","unstructured":"SAMHSA Opioid Treatment Program Guidance, March 16, 2021. https:\/\/www.samhsa.gov\/sites\/default\/files\/otp-guidance-20200316.pdf. Accessed 1 Sep 2022."},{"issue":"1","key":"372_CR5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13722-021-00275-1","volume":"16","author":"N Krawczyk","year":"2021","unstructured":"Krawczyk N, Fawole A, Yang J, Tofighi B. Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review. Addict Sci Clin Pract. 2021;16(1):68. https:\/\/doi.org\/10.1186\/s13722-021-00275-1.","journal-title":"Addict Sci Clin Pract"},{"key":"372_CR6","doi-asserted-by":"publisher","first-page":"108449","DOI":"10.1016\/j.jsat.2021.108449","volume":"131","author":"S Brothers","year":"2021","unstructured":"Brothers S, Viera A, Heimer R. Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19. J Subst Abuse Treat. 2021;131:108449. https:\/\/doi.org\/10.1016\/j.jsat.2021.108449.","journal-title":"J Subst Abuse Treat"},{"key":"372_CR7","doi-asserted-by":"publisher","first-page":"108223","DOI":"10.1016\/j.jsat.2020.108223","volume":"124","author":"MA Hatch-Maillette","year":"2021","unstructured":"Hatch-Maillette MA, Peavy KM, Tsui JI, Banta-Green CJ, Woolworth S, Grekin P. Re-thinking patient stability for methadone in opioid treatment programs during a global pandemic: provider perspectives. J Subst Abuse Treat. 2021;124:108223. https:\/\/doi.org\/10.1016\/j.jsat.2020.108223.","journal-title":"J Subst Abuse Treat"},{"key":"372_CR8","doi-asserted-by":"publisher","first-page":"108288","DOI":"10.1016\/j.jsat.2021.108288","volume":"124","author":"SB Hunter","year":"2021","unstructured":"Hunter SB, Dopp AR, Ober AJ, Uscher-Pines L. Clinician perspectives on methadone service delivery and the use of telemedicine during the COVID-19 pandemic: a qualitative study. J Subst Abuse Treat. 2021;124:108288. https:\/\/doi.org\/10.1016\/j.jsat.2021.108288.","journal-title":"J Subst Abuse Treat"},{"key":"372_CR9","doi-asserted-by":"publisher","first-page":"109100","DOI":"10.1016\/j.drugalcdep.2021.109100","volume":"228","author":"EF Madden","year":"2021","unstructured":"Madden EF, Christian BT, Lagisetty PA, Ray BR, Sulzer SH. Treatment provider perceptions of take-home methadone regulation before and during COVID-19. Drug Alcohol Depend. 2021;228:109100. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.109100.","journal-title":"Drug Alcohol Depend"},{"key":"372_CR10","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2021.306654","author":"LW Suen","year":"2022","unstructured":"Suen LW, Coe WH, Wyatt JP, Adams ZM, Gandhi M, Batchelor HM, Castellanos S, Joshi N, Satterwhite S, P\u00e9rez-Rodr\u00edguez R, Rodr\u00edguez-Guerra E. Structural adaptations to methadone maintenance treatment and take-home dosing for opioid use disorder in the era of COVID-19. AJPH. 2022. https:\/\/doi.org\/10.2105\/AJPH.2021.306654.","journal-title":"AJPH"},{"issue":"5","key":"372_CR11","doi-asserted-by":"publisher","first-page":"588","DOI":"10.5588\/ijtld.15.0738","volume":"20","author":"C Chuck","year":"2016","unstructured":"Chuck C, Robinson E, Macaraig M, Alexander M, Burzynski J. Enhancing management of tuberculosis treatment with video directly observed therapy in New York City. Int J Tuberc Lung Dis. 2016;20(5):588\u201393. https:\/\/doi.org\/10.5588\/ijtld.15.0738.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"4","key":"372_CR12","doi-asserted-by":"publisher","first-page":"ofy046","DOI":"10.1093\/ofid\/ofy046","volume":"5","author":"SB Holzman","year":"2018","unstructured":"Holzman SB, Zenilman A, Shah M. Advancing patient-centered care in tuberculosis management: a mixed-methods appraisal of video directly observed therapy. Open Forum Infect Dis. 2018;5(4):ofy046. https:\/\/doi.org\/10.1093\/ofid\/ofy046.","journal-title":"Open Forum Infect Dis"},{"issue":"10177","key":"372_CR13","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/S0140-6736(18)32993-3","volume":"393","author":"A Story","year":"2019","unstructured":"Story A, Aldridge RW, Smith CM, et al. Smartphone-enabled video-observed versus directly observed treatment for tuberculosis: a multicentre, analyst-blinded, randomised, controlled superiority trial. Lancet. 2019;393(10177):1216\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(18)32993-3.","journal-title":"Lancet"},{"key":"372_CR14","doi-asserted-by":"publisher","first-page":"108917","DOI":"10.1016\/j.drugalcdep.2021.108917","volume":"227","author":"JI Tsui","year":"2021","unstructured":"Tsui JI, Leroux BG, Radick AC, et al. Video directly observed therapy for patients receiving office-based buprenorphine\u2014A pilot randomized controlled trial. Drug Alcohol Depend. 2021;227:108917. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.108917.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"372_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/ADM.0000000000000608","volume":"14","author":"ME Godersky","year":"2020","unstructured":"Godersky ME, Klein JW, Merrill JO, et al. Acceptability and feasibility of a mobile health application for video directly observed therapy of buprenorphine for opioid use disorders in an office-based setting. J Addict Med. 2020;14(4):319\u201325. https:\/\/doi.org\/10.1097\/ADM.0000000000000608.","journal-title":"J Addict Med"},{"key":"372_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13722-019-0139-3","volume":"14","author":"ME Godersky","year":"2019","unstructured":"Godersky ME, Saxon AJ, Merrill JO, Samet JH, Simoni JM, Tsui JI. Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence. Addict Sci Clin Pract. 2019;14:11. https:\/\/doi.org\/10.1186\/s13722-019-0139-3.","journal-title":"Addict Sci Clin Pract"},{"key":"372_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108896","author":"KA Hallgren","year":"2022","unstructured":"Hallgren KA, Darnton J, Soth S, Blalock KL, Michaels A, Grekin P, Saxon AJ, Woolworth S, Tsui JI. Acceptability, feasibility, and outcomes of a clinical pilot program for video observation of methadone take-home dosing during the COVID-19 pandemic. J Subst Abuse Treat. 2022. https:\/\/doi.org\/10.1016\/j.jsat.2022.108896.","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"372_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101. https:\/\/doi.org\/10.1191\/1478088706qp063oa.","journal-title":"Qual Res Psychol"},{"issue":"11","key":"372_CR19","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.46743\/2160-3715\/2018.3560","volume":"23","author":"V Elliott","year":"2018","unstructured":"Elliott V. Thinking about the coding process in qualitative data analysis. Qual Rep. 2018;23(11):2850\u201361. https:\/\/doi.org\/10.46743\/2160-3715\/2018.3560.","journal-title":"Qual Rep"},{"key":"372_CR20","unstructured":"Maguire M, Delahunt B. Doing a thematic analysis: a practical, step-by-step guide for learning and teaching scholars. All Irel J High Educ. 2017;9(3). https:\/\/ojs.aishe.org\/index.php\/aishe-j\/article\/view\/335. Accessed 1 Sep 2022."},{"issue":"3","key":"372_CR21","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/ADM.0000000000000895","volume":"16","author":"JR Brooklyn","year":"2022","unstructured":"Brooklyn JR, Stothart M, Stunell M, Berman VM, Rylant D, Hanson M. Characterizing the clinical use of a novel video-assisted dosing protocol with secure medication dispensers to reduce barriers to opioid treatment. J Addict Med. 2022;16(3):310\u20136. https:\/\/doi.org\/10.1097\/ADM.0000000000000895.","journal-title":"J Addict Med"},{"issue":"9","key":"372_CR22","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1001\/jama.2022.1271","volume":"327","author":"T Gomes","year":"2022","unstructured":"Gomes T, Campbell TJ, Kitchen SA, et al. Association between increased dispensing of opioid agonist therapy take-home doses and opioid overdose and treatment interruption and discontinuation. JAMA. 2022;327(9):846\u201355. https:\/\/doi.org\/10.1001\/jama.2022.1271.","journal-title":"JAMA"},{"key":"372_CR23","doi-asserted-by":"publisher","first-page":"103591","DOI":"10.1016\/j.drugpo.2022.103591","volume":"102","author":"C Welsh","year":"2022","unstructured":"Welsh C, Doyon S, Hart K. Methadone exposures reported to poison control centers in the United States following the COVID-19-related loosening of federal methadone regulations. Int J Drug Policy. 2022;102:103591. https:\/\/doi.org\/10.1016\/j.drugpo.2022.103591.","journal-title":"Int J Drug Policy"},{"key":"372_CR24","doi-asserted-by":"publisher","first-page":"108590","DOI":"10.1016\/j.jsat.2021.108590","volume":"133","author":"G Bart","year":"2022","unstructured":"Bart G, Wastvedt S, Hodges JS, Rosenthal R. Did drug use increase following COVID-19 relaxation of methadone take-out regulations? 2020 was a complicated year. J Subst Abuse Treat. 2022;133:108590. https:\/\/doi.org\/10.1016\/j.jsat.2021.108590.","journal-title":"J Subst Abuse Treat"},{"key":"372_CR25","doi-asserted-by":"publisher","first-page":"108552","DOI":"10.1016\/j.jsat.2021.108552","volume":"133","author":"O Amram","year":"2022","unstructured":"Amram O, Amiri S, Thorn EL, Lutz R, Joudrey PJ. Changes in methadone take-home dosing before and after COVID-19. J Subst Abuse Treat. 2022;133:108552. https:\/\/doi.org\/10.1016\/j.jsat.2021.108552.","journal-title":"J Subst Abuse Treat"},{"key":"372_CR26","doi-asserted-by":"publisher","first-page":"108219","DOI":"10.1016\/j.jsat.2020.108219","volume":"122","author":"G Joseph","year":"2021","unstructured":"Joseph G, Torres-Lockhart K, Stein MR, Mund PA, Nahvi S. Reimagining patient-centered care in opioid treatment programs: lessons from the Bronx during COVID-19. J Subst Abuse Treat. 2021;122:108219. https:\/\/doi.org\/10.1016\/j.jsat.2020.108219.","journal-title":"J Subst Abuse Treat"},{"key":"372_CR27","unstructured":"Opioid treatment programs reported challenges encountered during the COVID-19 pandemic and actions taken to address them. https:\/\/oig.hhs.gov\/oas\/reports\/region9\/92001001.asp. Accessed 1 Sep 2022."},{"issue":"12","key":"372_CR28","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1176\/appi.ps.202000226","volume":"71","author":"Y Bao","year":"2020","unstructured":"Bao Y, Williams AR, Schackman BR. COVID-19 can change the way we respond to the opioid crisis\u2014for the better. Psychiatr Serv. 2020;71(12):1214\u20135. https:\/\/doi.org\/10.1176\/appi.ps.202000226.","journal-title":"Psychiatr Serv"},{"issue":"10","key":"372_CR29","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1016\/j.mayocp.2020.08.011","volume":"95","author":"AD Greenblatt","year":"2020","unstructured":"Greenblatt AD, Magidson JF, Belcher AM, Gandhi D, Weintraub E. Overdue for an overhaul: how opioid treatment programs can learn from COVID-19. Mayo Clin Proc. 2020;95(10):2076\u20138. https:\/\/doi.org\/10.1016\/j.mayocp.2020.08.011.","journal-title":"Mayo Clin Proc"},{"key":"372_CR30","doi-asserted-by":"publisher","first-page":"108074","DOI":"10.1016\/j.jsat.2020.108074","volume":"117","author":"N Krawczyk","year":"2020","unstructured":"Krawczyk N, Fingerhood MI, Agus D. Lessons from COVID 19: are we finally ready to make opioid treatment accessible? J Subst Abuse Treat. 2020;117:108074. https:\/\/doi.org\/10.1016\/j.jsat.2020.108074.","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"372_CR31","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/ADM.0000000000000678","volume":"14","author":"IE Leppla","year":"2020","unstructured":"Leppla IE, Gross MS. Optimizing medication treatment of opioid use disorder during COVID-19 (SARS-CoV-2). J Addict Med. 2020;14(4):e1\u20133. https:\/\/doi.org\/10.1097\/ADM.0000000000000678.","journal-title":"J Addict Med"},{"key":"372_CR32","doi-asserted-by":"publisher","first-page":"108544","DOI":"10.1016\/j.jsat.2021.108544","volume":"133","author":"C Lin","year":"2022","unstructured":"Lin C, Clingan SE, Cousins SJ, Valdez J, Mooney LJ, Hser YI. The impact of COVID-19 on substance use disorder treatment in California: service providers\u2019 perspectives. J Subst Abuse Treat. 2022;133:108544. https:\/\/doi.org\/10.1016\/j.jsat.2021.108544.","journal-title":"J Subst Abuse Treat"},{"key":"372_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/0147-1767(85)90062-8","volume-title":"Naturalistic inquiry","author":"YS Lincoln","year":"1985","unstructured":"Lincoln YS, Guba EG. Naturalistic inquiry. Newbury Park: Sage Publications; 1985."}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-023-00372-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-023-00372-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-023-00372-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T12:07:36Z","timestamp":1680091656000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-023-00372-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,29]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["372"],"URL":"https:\/\/doi.org\/10.1186\/s13722-023-00372-3","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,29]]},"assertion":[{"value":"29 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The procedures for the program evaluation of the VOT pilot were approved by the University of Washington Institutional Review Board. All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}